Novartis Case Tests India's IP Climate

Law360, New York (January 10, 2007, 12:00 AM EST) -- Novartis AG’s ongoing battle to patent its cancer treatment Gleevec in India has seen the drug maker challenge not only the rejection of its patent application earlier this year, but a key section of India’s recently enacted patent laws – a maneuver that intellectual property lawyers say could be a litmus test for multinational pharmaceutical companies testing legal waters in the country.

Since the Chennai Patent Office rejected Novartis’ patent application in January 2006 on the grounds that Gleevec was not significantly different in properties from...
To view the full article, register now.